On March 30, 2026, SCYNEXIS, Inc. announced the completion of an asset purchase agreement with Poxel SA, acquiring all rights to Poxel's direct AMP kinase activator research and development program assets, including the compound PXL-770, now renamed SCY-770. The agreement includes an upfront payment of $8 million, with additional milestone payments potentially totaling up to $188 million based on the achievement of specific development and commercial milestones. These milestones include payments for the initiation of clinical trials and sales targets, reflecting SCYNEXIS's commitment to advancing innovative therapies for severe and rare diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD). The acquisition is expected to enhance SCYNEXIS's pipeline and provide significant opportunities for value creation in a market with high unmet medical needs. A Phase 2 proof-of-concept study for SCY-770 is anticipated to begin in Q4 2026, with early efficacy results expected in the second half of 2027. This strategic move positions SCYNEXIS to leverage its development expertise and resources to tackle the challenges associated with ADPKD, a condition that currently has limited treatment options. The company plans to host a conference call on March 31, 2026, to discuss the transaction and provide further corporate updates.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.